Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Western Alliance Bancorporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Western Alliance Bancorporation trades at $80.69 (market cap $8.81B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 4.5× Western Alliance Bancorporation's market cap, and Western Alliance Bancorporation pays a 2.08% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | WAL | |
|---|---|---|
Market Cap | $39.89B | $8.81B |
Sector | Health | Financials |
52-Week High | $491.22 | $96.08 |
52-Week Low | $278.09 | $66.70 |
Enterprise Value | $38.15B | — |
Dividend Yield | — | 2.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Western Alliance Bancorporation (WAL) trades at $80.69, up 0.85% on the day, with a bearish technical signal from moving averages but neutral oscillators. The stock shows strong fundamentals with a P/E of 9.39 and net income margin of 25.63%, supported by three consecutive quarterly earnings beats. Recent news highlights business expansion, including a $33 million Las Vegas redevelopment loan and recognition as Arizona's top bank by Forbes in 2026.
The outlook is positive given analyst consensus with a $90.67 price target and 79% buy ratings, though risks include negative operating cash flow and high interest expenses. Earnings growth and strategic hires in commercial real estate and entertainment financing present opportunities, but investor caution is warranted near technical resistance at $82.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
